Swiss Life Sciences Group Launches CBD Funding Platform

A new platform designed to provide financing and credit facilities to fast-growing companies and brands operating in the cannabis and CBD industry has been introduced by Swiss Life Sciences Group.

The platform which will primarily target companies operating in the medical and pharmaceutical sectors allows the issuance of notes to professional investors in the EU and UK financial markets and a wrapper facility [specifically for the French market].

The Swiss Life Sciences Group which specialises in production, cultivation, genetics and manufacturing in the CBD pharmaceutical and nutraceuticals space, has chosen Luxembourg as a domicile of choice for the setup of a securitisation vehicle as a highly specialised platform for the CBD industry, to raise funds from the institutional, HNWI and family-office investor space, according to a press release…

Continue reading on Cannyxnews.com